"Novavax's COVID-19 Vaccine Receives FDA Approval with Restrictions: What You Need to Know"
Read "Novavax's COVID-19 Vaccine Receives FDA Approval with Restrictions: What You Need to Know" on WALY Radio
"Novavax's COVID-19 Vaccine Receives FDA Approval with Restrictions: What You Need to Know"
[!CDATA[The Food and Drug Administration has granted full approval to Novavax's COVID-19 vaccine with specific restrictions. The vaccine is now approved for use in adults 65 and older, as well as individuals aged 12 to 64 with underlying health conditions that increase their risk from COVID-19. This approval sets Novavax apart from its competitors Pfizer and Moderna, whose vaccines are fully licensed for use in anyone 12 and older, including children as young as 6 months. The decision by the FDA to restrict the use of Novavax's vaccine comes ahead of a meeting next month where CDC advisers will discuss whether yearly COVID vaccines should be recommended for everyone or only certain high-risk individuals. Novavax CEO John C. Jacobs welcomed the licensure, emphasizing the company's commitment to older individuals and those with underlying health conditions who are most likely to seek out COVID-19 vaccination seasonally. Despite showing safety and efficacy in a 30,000-person clinical trial, Novavax faced unexpected hurdles in the approval process. The FDA requested additional trials to be completed in the next few years, including studies on potential associations with heart conditions and the benefits of continued vaccination in 50- to 64-year-olds without underlying health risks from COVID-19. The approval of Novavax's COVID-19 vaccine with restrictions underscores the company's dedication to providing a protein-based vaccine option for vulnerable populations. As the landscape of COVID-19 vaccination evolves, Novavax remains committed to ensuring the safety and efficacy of its vaccine for those most at risk from the virus.]]